Helsinn

Focus: Helsinn is a small-molecule biotech focused on oncology and gastroenterology with a portfolio of marketed and pipeline assets. The company operates with significant revenue concentration (72%) from its flagship product VALCHLOR.

Oncology Gastroenterology

Profile data last refreshed 15h ago · AI intelligence enriched 3w ago

Open Jobs

About Helsinn

AI assessmentNot Hiring

No open roles listed right now. Follow Helsinn to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

14 Phase 3+

LOE Risk

1 in 5yr

VALCHLOR

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

VALCHLOR

Alkylating Drug

$13M

Peak2.9yr

Help build intelligence for Helsinn

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Amixea

Cancer Patients With Cachexia

N/A

Clinical Trials (1)

NCT02877966Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer

N/A

Aqualief

Xerostomia

N/A

Clinical Trials (1)

NCT03601962Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

N/A

Standardized Ginger extract

Cancer

N/A

Clinical Trials (1)

NCT01887314Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy

N/A

Somnage

Breast Cancer

N/A

Clinical Trials (1)

NCT02883790Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients

N/A

Xonrid® gel

Radiodermatitis

N/A

Clinical Trials (1)

NCT03255980Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®

N/A

Valchlor

Mycosis Fungoides

N/A

Clinical Trials (1)

NCT02296164Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

N/A

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd

N/A

Clinical Trials (1)

NCT07132749NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

N/A

Pracinostat

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02118909Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

Phase 1

Infigratinib

Cholangiocarcinoma

Phase 1

Clinical Trials (1)

NCT05510427Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase 1

Fosnetupitant 235 mg solution

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06840769A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers

Phase 1

pracinostat

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02058784Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects

Phase 1

pracinostat

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03495934A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body

Phase 1

Infigratinib

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05222165Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Phase 1/2

IV NEPA

Nausea and Vomiting Chemotherapy-Induced

Phase 2

Clinical Trials (1)

NCT06904235Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

Phase 2

Elsiglutide

Drug and/or Toxin-induced Diarrhea

Phase 2

Clinical Trials (1)

NCT02383810Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)

Phase 2

Palonosetron

Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT00306735Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Phase 2

Elsiglutide

Diarrhea

Phase 2

Clinical Trials (1)

NCT01543451Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

Phase 2

Netupitant

Malignant Neoplasm

Phase 2

Clinical Trials (1)

NCT03097588Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Phase 2

Pracinostat

Myelodysplastic Syndromes

Phase 2

Clinical Trials (1)

NCT03151304A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Phase 2

Akynzeo

Chemotherapy Induced Nausea and Vomiting

Phase 2

Clinical Trials (1)

NCT06065722Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Phase 2

BGJ398

Advanced Cholangiocarcinoma

Phase 2

pracinostat

Myelodysplastic Syndrome

Phase 2

Clinical Trials (1)

NCT01993641Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Phase 2

Ruxolitinib

Myeloproliferative Diseases

Phase 2

Clinical Trials (1)

NCT02267278Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Phase 2

Pracinostat

Acute Myeloid Leukemia

Phase 2

Clinical Trials (1)

NCT01912274Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 2

pracinostat

Myelodysplastic Syndrome

Phase 2

Clinical Trials (1)

NCT01873703Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Phase 2

Netupitant

Chemotherapy-induced Nausea and Vomiting (CINV)

Phase 2

Clinical Trials (1)

NCT03204279PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

Phase 2

Saline Solution for Injection

Gastrointestinal Dysmotility

Phase 2

Clinical Trials (1)

NCT01280344Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

Phase 2

RC-1291

Cancer Cachexia

Phase 2

Clinical Trials (1)

NCT00378131Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

Phase 2

RC-1291 HCl

Cancer Cachexia

Phase 2

Clinical Trials (1)

NCT00219817Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Phase 2

anamorelin HCl

Carcinoma, Non-Small-Cell Lung

Phase 2

Clinical Trials (1)

NCT00622193Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Phase 2

RC-1291 HCl

Cancer Cachexia

Phase 2

Clinical Trials (1)

NCT00267358Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

Phase 2

Anamorelin HCl

Cancer Cachexia

Phase 2

Clinical Trials (1)

NCT01505764The Role of Ghrelin in Cancer Cachexia

Phase 2

Ipamorelin

Ileus

Phase 2

Clinical Trials (1)

NCT00672074Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

Phase 2

Anamorelin Hydrochloride

Metastatic Pancreatic Cancer

Phase 2

Clinical Trials (1)

NCT04844970Anamorelin Study for Advanced Pancreatic Cancer

Phase 2

Netupitant

Malignant Neoplasm

Phase 2/3

Clinical Trials (1)

NCT03040726Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Phase 2/3

Akynzeo

Chemotherapy-induced Nausea and Vomiting

Phase 2/3

Clinical Trials (1)

NCT03668639Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Phase 2/3

Pro-netupitant/Palonosetron

Chemotherapy-Induced Nausea and Vomiting

Phase 3

Clinical Trials (1)

NCT02517021A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

Phase 3

Anamorelin HCl

Cachexia

Phase 3

Clinical Trials (1)

NCT01387282Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Phase 3

Infigratinib

Upper Tract Urothelial Carcinomas

Phase 3

BGJ398

Advanced Cholangiocarcinoma

Phase 3

Anamorelin HCl

Cachexia

Phase 3

Clinical Trials (1)

NCT01395914Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Phase 3

anamorelin HCl

Cachexia; Cancer

Phase 3

Clinical Trials (1)

NCT03743064A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Netupitant and Palonosetron

Chemotherapy-Induced Nausea and Vomiting

Phase 3

Clinical Trials (1)

NCT01339260An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Phase 3

Pracinostat

Acute Myeloid Leukemia

Phase 3

Clinical Trials (1)

NCT03151408An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Phase 3

Anamorelin Hydrochloride

Cachexia; Cancer

Phase 3

Clinical Trials (1)

NCT03743051A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3

fosnetupitant/ palonosetron

Chemotherapy-induced Nausea and Vomiting

Phase 3

Clinical Trials (1)

NCT03403712A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Phase 3

Netupitant and Palonosetron

Chemotherapy-Induced Nausea and Vomiting

Phase 3

Clinical Trials (1)

NCT01376297A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Phase 3

Fosaprepitant dimeglumine

Nausea

Phase 3

Clinical Trials (1)

NCT01074697Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Phase 3

Oral palonosetron

Chemotherapy-Induced Nausea and Vomiting

Phase 3

Clinical Trials (1)

NCT01363479An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

Phase 3

palonosetron

Postoperative Nausea and Vomiting

Phase 3

Clinical Trials (1)

NCT00828295Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Phase 3

Helsinn

About Helsinn

Why Work Here

Key Products

Watch Out For

Products & Portfolio (3)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)